Le Lézard
Classified in: Health
Subjects: SVY, BFA, TRI

Diagnosing, Treating Sleep Apnea in Hospital Improves Survival, Says Study Published by American Journal of Medicine

SAN DIEGO, Jan. 3, 2018 /PRNewswire/ -- Undiagnosed sleep apnea is highly prevalent among hospital patients, and treating it after they're discharged can improve their chances of long-term survival, according to a ResMed-funded (NYSE: RMD, ASX: RMD) study published in the American Journal of Medicine.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/74629529-resmed-sleep-apnea-study/

The study screened more than 5,000 hospitalized patients; 18.7 percent were estimated to have sleep apnea. Those who tested positive for sleep apnea were placed on positive airway pressure (PAP) therapy post-discharge. Patients who were adherent to therapy in the first three months had an improved chance of survival over the next 20 months, compared with those not adherent on PAP.

"We have a profound opportunity to identify and help tens of thousands of hospitalized patients who don't know they have a dangerous but treatable sleep condition," said Sunil Sharma, M.D., the study's principal investigator. "These results show just how important a hospital can be in addressing these issues."

"Up to 70 million Americans have sleep apnea, and only a fraction are diagnosed," said ResMed Chief Medical Officer Carlos M. Nunez, M.D. "When a medical condition brings them to a hospital, it's a prime opportunity to see if they also have sleep apnea, which they can then address ? and potentially live longer for doing so."

Read the study in the American Journal of Medicine: http://www.amjmed.com/article/S0002-9343(17)30399-6/abstract

About the study
This was a clinical pathway evaluation where 5,062 patients admitted to the Cardiology, Internal Medicine and Family Practice services with a BMI ? 30 were screened from March 2013 to July 2016. The study was approved by an Institutional Review Board. Funding support from an unrestricted grant from ResMed.

About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 4 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients' quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com | Facebook | Twitter | LinkedIn

For media:

For investors:

Alison Graves

Agnes Lee

+1 858-836-6789

+1 858-836-5971




ResMed Inc. logo. (PRNewsFoto/ResMed Inc.) (PRNewsFoto/RESMED INC.)


Logo - https://mma.prnewswire.com/media/588826/RESMED_INC__LOGO.jpg

These press releases may also interest you

at 06:00
Transparency Market Research (TMR) has published a new report titled, "Plasma Fractionation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026". According to the report, the global plasma fractionation market was...

at 06:00
Marken announced today that Brazil's ANVISA has approved shipments of biological samples from Sao Paulo's Viracopos airport to the United States using the UPS airline. The pilot program approved by the Brazilian authorities will allow biologic...

at 06:00
DENVER, Aug. 21, 2018 /PRNewswire-PRWeb/ -- Enquire, a leading provider of cloud CRM and sales contact center solutions for senior living and post-acute communities, is proud to announce Linkmedia 360 as the Diamond Sponsor of Enquire Summit,...

at 06:00
BEVERLY HILLS, Calif., Aug. 21, 2018 /PRNewswire-PRWeb/ -- The Centers for Disease Control and Prevention (CDC) just released provisional data showing 70,689 drug overdose deaths in 2017. This is the highest overdose death rate on record and reflects...

at 06:00
The "Surgical Suture Market to 2025 - Global Analysis and Forecasts By Product, Application and Geography" report has been added to ResearchAndMarkets.com's offering. While conducting the study for surgical sutures, we have segmented the surgical...

at 06:00
Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $3 million Small Business Innovation Research (SBIR) grant from the National Institutes of...

News published on 3 january 2018 at 09:00 and distributed by: